Start Your Search
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.01-069 - Reasons for Discontinuation of Treatment with Bevacizumab in Patients with Non-Progressing NSCLC - Retrospective Study (ID 3243)
09:30 - 17:00 | Author(s): L. Dolakova
In general, bevacizumab is well-tolerated treatment in patients with advanced, metastatic non-squamous NSCLC. Despite this, permanent discontinuations of bevacizumab occur also before progressive disease (PD), both in clinical trials and in clinical practice. Purpose of this study was to find out the reasons for permanent discontinuation of bevacizumab before PD in patients treated in two centers in the Slovak republic.
In this retrospective study, approved by the Ethics Committee of the Specialized Hospital of St Zoerardus Zobor, the institutional databases were searched for patients with advanced NSCLC treated with bevacizumab between 2007 and 2013.
Altogether 161 patients were included into the analysis. Patients' characteristics: M/W: 99/62, age: median 61 years (32 - 83), histologically /cytologically confirmed NSCLC: adenocarcinoma/large cell/adenosquamous: 158/2/1. Number of cycles with bevacizumab (induction and maintenance): median 8 (1 - 52), PFS: median 7 months (1 - 42). Bevacizumab was permanently discontinued before PD in 28 of 161 patients (17,4%), in 18 of 161 (11,2%) due to undesirable effects - Table 1. Table 1: Reasons for permanent discontinuation of bevacizumab in non-progressing NSCLC
Undesirable effects N Other reasons N Cavitation 3 Lost to FU 2 Pneumothoraces 3 Molecular testing, start of TKI 2 Cerebrovascular event 2 Patients' preference 2 Gastrointestinal perforation 2 Car accident, death 1 Hypertensive crisis 2 Planned surgery 1 Pneumonia 2 Traumatic fractures 1 Proteinuria 2 Other 1 Thrombotic event 2 All 18 All 10
Permanent discontinuation of bevacizumab in non-progressing NSCLC was seen in this study in the similar rate as in the larger trials (Wozniak AJ et al. Clin Oncol [Coll Radiol]. 2015, 27:187-96.) However, some differences are in the type of undesirable effects, which are in part also chemotherapy related.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.